Isolation of the Stromal Vascular Fraction Using a New Protocol with All Clinical-Grade Drugs: From Basic Study to...

Area of Science:

• Regenerative Medicine
• Cell Biology
• Biotechnology

Background:

• The stromal vascular fraction (SVF) is a cell population derived from adipose tissue.
• Evaluating novel isolation protocols is crucial for clinical applications of SVF.

Purpose of the Study:

• To assess the yield, viability, safety, and efficacy of SVF isolated using a new clinical protocol.
• To compare the new clinical protocol with a standard laboratory protocol.

Main Methods:

• SVF was isolated from 13 participants using both a new clinical protocol and a laboratory protocol.
• Key parameters evaluated included cell yield, viability, morphology, mesenchymal stem cell (MSC) marker expression, and differentiation potential.
• Three clinical trials were conducted to assess the safety and efficacy of the clinically isolated SVF.

Main Results:

• No significant differences were observed in SVF yield, viability, morphology, or differentiation between the two protocols.
• Mesenchymal stem cell (MSC) surface marker expression (CD14, CD31, CD44, CD90, CD105, CD133) was consistent across both isolation methods.
• Clinical trials confirmed the effectiveness of the new protocol's SVF in enhancing skin grafting, promoting regeneration under mechanical stretch, and improving facial skin texture, with no reported complications.

Conclusions:

• The new clinical protocol for SVF isolation is non-inferior to the laboratory protocol in terms of yield and viability.
• SVF obtained via the new clinical protocol demonstrates safe and effective therapeutic potential for various dermatological applications, including skin regeneration and texture improvement.